Spots Global Cancer Trial Database for lymphodepleting chemotherapy
Every month we try and update this database with for lymphodepleting chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | NCT06383572 | Lymphodepleting... Myeloid Maligna... | Cyclophosphamid... Fludarabine pho... Decitabine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601 | Solid Tumors Brain Tumors Sarcoma Pediatric Cance... Neuroblastoma | Recombinant hum... NK Cell Infusio... | 2 Years - 29 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | NCT06383572 | Lymphodepleting... Myeloid Maligna... | Cyclophosphamid... Fludarabine pho... Decitabine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Vemurafenib and TIL Therapy for Metastatic Melanoma | NCT02354690 | Metastatic Mela... | Vemurafenib Lymphodepleting... TIL infusion Interleukin-2 | 18 Years - 70 Years | Herlev Hospital | |
| Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | NCT06105021 | Pancreatic Duct... Non-Small Cell ... Colorectal Canc... Solid Tumor KRAS G12V | AFNT-211 | 18 Years - | Affini-T Therapeutics, Inc. | |
| Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | NCT06358430 | Colorectal Canc... Minimal Residua... | Fludarabine Pho... Cyclophosphamid... Cetuximab TROP2-CAR-NK Ce... Rimiducid (AP19... Lymphodepleting... | 18 Years - | M.D. Anderson Cancer Center | |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | NCT06340737 | Follicular Lymp... Mantle Cell Lym... Hairy Cell Leuk... Lymphoplasmacyt... Burkitt Lymphom... Marginal Zone L... Waldenstrom Mac... | CD22CART Infusi... | 18 Years - | Stanford University | |
| Vemurafenib and TIL Therapy for Metastatic Melanoma | NCT02354690 | Metastatic Mela... | Vemurafenib Lymphodepleting... TIL infusion Interleukin-2 | 18 Years - 70 Years | Herlev Hospital | |
| Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma | NCT06185751 | Multiple Myelom... | WS-CART-CS1 Lymphodepleting... | 18 Years - | Washington University School of Medicine | |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601 | Solid Tumors Brain Tumors Sarcoma Pediatric Cance... Neuroblastoma | Recombinant hum... NK Cell Infusio... | 2 Years - 29 Years | National Institutes of Health Clinical Center (CC) | |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601 | Solid Tumors Brain Tumors Sarcoma Pediatric Cance... Neuroblastoma | Recombinant hum... NK Cell Infusio... | 2 Years - 29 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
